citizen reporter. october 2007  (19).-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018..

despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6...

..

.

.

meet other global citizens who care about the same issues you do. keep updated on what they're doing to change the world.